Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
Sofosbuvir & ravidasvir delivers high sustained response rates for genotype 4 hepatitis C patients

A regimen of sofosbuvir and the pan-genotypic HCV NS5A inhibitor ravidasvir, with or without ribavirin, demonstrated sustained response rates ranging from 86% to 100% in the

Published
17 November 2015
By
Liz Highleyman
Treatment intensification with sofosbuvir permits cure after failure of previous HCV treatment

Re-treating with an interferon-free regimen that previously failed to cure hepatitis C can result in success if treatment is intensified with the addition of sofosbuvir, two studies

Published
17 November 2015
By
Keith Alcorn
New AbbVie hepatitis C pan-genotypic combination cures 97 to 100% in early study

A combination of two experimental direct-acting antivirals developed by AbbVie cured 97 to 100% of non-cirrhotic people with genotype 1 hepatitis C infection in a mid-stage phase

Published
16 November 2015
By
Keith Alcorn
Sofosbuvir/velpatasvir + GS-9857 for 8 weeks cures hepatitis C for most people with genotype 1 or 3

An 8-week triple combination of Gilead Sciences' sofosbuvir, velpatasvir and GS-9857 showed a high sustained response rate in a phase 2 study of people with difficult-to-treat hepatitis

Published
16 November 2015
By
Liz Highleyman
Grazoprevir/elbasvir shows high hepatitis C cure rate for people who inject drugs

Merck's grazoprevir/elbasvir co-formulation cured hepatitis C infection in 92% of people who inject drugs (PWID) who received opioid substitution therapy in the C-EDGE CO-STAR study,

Published
16 November 2015
By
Liz Highleyman
Study suggests unprecedented 3-week hepatitis C cure

Yet another stunning victory in the drug battle against the liver-damaging hepatitis C virus (HCV) may be in the offing: A small study suggests it may be possible to cure some people of their infections in as few as 3 weeks.

Published
02 November 2015
From
Science
Gilead Seeks FDA Approval for Hep C Treatment for All Genotypes

Gilead has applied to the FDA for approval of the combo tablet of Sovaldi and velpatasvir to treat those with genotypes 1 through 6 of hepatitis C.

Published
02 November 2015
From
AIDSMeds
'Dallas Buyers' Club' for Hep C treatments under investigation

A "Dallas Buyers Club" of doctors and patients importing potentially life-saving Hepatitis C medication from countries like China is being investigated by the Therapeutic Goods Administration.

Published
22 October 2015
From
Sydney Morning Herald
NICE Recommends Daklinza (daclatasvir) for Treatment of Certain Patients with Chronic Hepatitis C Genotypes 1, 3 and 4

Bristol-Myers Squibb today announced that the National Institute for Health and Care Excellence (NICE) has recommended Daklinza (daclatasvir) in England and Wales for the treatment of adult patients with chronic hepatitis C virus (HCV) infection. Specifically, NICE recommended Daklinza, an oral, once-daily medication used in combination with other agents, to treat certain patients with HCV genotypes 1, 3 and 4.

Published
16 October 2015
From
Bristol-Myers Squibb press release
U.S. FDA Grants Priority Review For Daklinza (daclatasvir) sNDAs

Three applications are under review for Daklinza in combination with sofosbuvir with or without ribavirin to treat chronic hepatitis C patients with decompensated cirrhosis, post-liver transplant recurrence of HCV, and coinfection with HIV-1.

Published
07 October 2015
From
Bristol-Myers Squibb

Filter by country